Latest:
Dr. Duruisseaux on the Incidence of NRG1 Fusions in Solid Tumors
Michaël Duruisseaux, MD, a medical oncologist at Lyon Cancer Institute in France, discusses the incidence of NRG1 fusions in solid tumors.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Michael Folkert, MD, PhD
Latest:
Stereotactic Radiation Potential Emerges in Prostate Cancer
Stereotactic ablative radiosurgery, which is administered in far fewer but larger doses than conventional radiotherapy, has the potential to benefit a substantial proportion of patients with low-, intermediate-, and potentially even high-risk prostate cancers.
Michael Gnant, MD
Latest:
Dr. Michael Gnant on the PAM50 Breast Cancer Intrinsic Subtypes
Michael Gnant, MD, professor of the Department of Surgery at the Medical University of Vienna in Vienna, Austria, discusses the four intrinsic subtypes of the PAM50 recurrence score test and a clinical trial comparing this test with OncotypeDX.
Michael Hoerger, PhD, MSCR
Latest:
Informed Patients Are More Likely to Choose Palliative Care
Research from Tulane University provides a strong case that, across demographic and clinical populations, informed patients are less wary of palliative care and more inclined to take advantage of the favorable effects that palliative care services can offer for patient-centered outcomes.
Michael I. D'Angelica, MD, FACS
Latest:
Hepatic Infusion Can Convert CRC Liver Metastases to Operable State
Overall, compelling response rates and rates of conversion to resection for patients with initially unresectable colorectal liver metastases treated with hepatic arterial infusion suggest consideration of earlier initiation of the technique in chemotherapy-naïve patients as well as its adoption in patients who have failed first-line systemic chemotherapy before proceeding to second- or third-line regimens.
Michael J. Guarino, MD
Latest:
Dr. Guarino on IMMU-132 in Advanced Metastatic Lung Cancer
Michael J. Guarino, MD, senior staff member, Christiana Care's Department of Medicine, partner, Medical Oncology Hematology Consultants, Christiana Care's Helen F. Graham Cancer Center, discusses initial data from a phase I/ll study examining an anti-ΤROP-2-SN-38 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), as therapy for advanced metastatic lung cancer.
Michael J. Hall, MD, MS
Latest:
Dr. Hall on the Importance of Genetic Testing in Pancreatic Cancer
Michael J. Hall, MD, MS, chair, Department of Clinical Genetics, director, Gastrointestinal Risk Assessment, associate professor, Fox Chase Cancer Center, discusses the importance of genetic testing in pancreatic cancer.
Michael J. Keating, MD, BS
Latest:
Rituximab for Chronic Lymphocytic Leukemia in Treatment-Naïve and Treatment-Experienced Patients
A mixed treatment comparison demonstrated that FCR significantly prolonged PFS compared with all other treatments and significantly increased ORR compared with all other treatments.